Sernova Corp. (SVA.TO)
CAD 0.17
(-5.88%)
CAD 0.17
(-5.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.59 Million CAD | 96.71% |
| 2022 | 4.87 Million CAD | 178.35% |
| 2021 | 1.75 Million CAD | 10.83% |
| 2020 | 1.58 Million CAD | 130.14% |
| 2019 | 686.82 Thousand CAD | 101.3% |
| 2018 | 341.2 Thousand CAD | -62.13% |
| 2017 | 901.06 Thousand CAD | 6.47% |
| 2016 | 846.27 Thousand CAD | 323.45% |
| 2015 | 199.85 Thousand CAD | -16.76% |
| 2014 | 240.08 Thousand CAD | 6.64% |
| 2013 | 225.14 Thousand CAD | 68.08% |
| 2012 | 133.95 Thousand CAD | 12.5% |
| 2011 | 119.06 Thousand CAD | -17.31% |
| 2010 | 143.99 Thousand CAD | 40.87% |
| 2009 | 102.22 Thousand CAD | -15.41% |
| 2008 | 120.84 Thousand CAD | 252.45% |
| 2007 | 34.28 Thousand CAD | -71.93% |
| 2006 | 122.15 Thousand CAD | -49.57% |
| 2005 | 242.23 Thousand CAD | 38.6% |
| 2004 | 174.78 Thousand CAD | -4.17% |
| 2003 | 182.39 Thousand CAD | -2.82% |
| 2002 | 187.67 Thousand CAD | -58.07% |
| 2001 | 447.62 Thousand CAD | 233.85% |
| 2000 | 134.08 Thousand CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 14.73 Million CAD | 53.65% |
| 2024 Q2 | 17.26 Million CAD | 17.17% |
| 2024 Q3 | 20 Million CAD | 15.84% |
| 2023 FY | 9.59 Million CAD | 96.71% |
| 2023 Q4 | 9.59 Million CAD | -3.45% |
| 2023 Q1 | 6.42 Million CAD | 31.78% |
| 2023 Q3 | 9.93 Million CAD | 68.12% |
| 2023 Q2 | 5.9 Million CAD | -8.04% |
| 2022 FY | 4.87 Million CAD | 178.35% |
| 2022 Q2 | 2.9 Million CAD | 28.27% |
| 2022 Q3 | 2.53 Million CAD | -12.92% |
| 2022 Q1 | 2.26 Million CAD | 29.48% |
| 2022 Q4 | 4.87 Million CAD | 92.45% |
| 2021 Q1 | 881.71 Thousand CAD | -44.22% |
| 2021 Q3 | 1.08 Million CAD | -17.27% |
| 2021 FY | 1.75 Million CAD | 10.83% |
| 2021 Q4 | 1.75 Million CAD | 61.15% |
| 2021 Q2 | 1.31 Million CAD | 49.04% |
| 2020 Q1 | 471.96 Thousand CAD | -31.28% |
| 2020 Q3 | 1.42 Million CAD | 43.65% |
| 2020 Q4 | 1.58 Million CAD | 10.9% |
| 2020 FY | 1.58 Million CAD | 130.14% |
| 2020 Q2 | 992.24 Thousand CAD | 110.24% |
| 2019 Q1 | 333.68 Thousand CAD | -2.2% |
| 2019 Q4 | 686.82 Thousand CAD | 145.0% |
| 2019 Q3 | 280.34 Thousand CAD | -50.84% |
| 2019 FY | 686.82 Thousand CAD | 101.3% |
| 2019 Q2 | 570.25 Thousand CAD | 70.9% |
| 2018 Q3 | 489.2 Thousand CAD | -4.44% |
| 2018 Q4 | 341.2 Thousand CAD | -30.25% |
| 2018 Q1 | 567.45 Thousand CAD | -37.02% |
| 2018 Q2 | 511.92 Thousand CAD | -9.79% |
| 2018 FY | 341.2 Thousand CAD | -62.13% |
| 2017 Q4 | 901.06 Thousand CAD | -17.66% |
| 2017 FY | 901.06 Thousand CAD | 6.47% |
| 2017 Q3 | 1.09 Million CAD | 55.25% |
| 2017 Q2 | 704.89 Thousand CAD | -5.92% |
| 2017 Q1 | 749.25 Thousand CAD | -11.46% |
| 2016 FY | 846.27 Thousand CAD | 323.45% |
| 2016 Q4 | 846.27 Thousand CAD | -22.99% |
| 2016 Q3 | 1.09 Million CAD | 4.66% |
| 2016 Q2 | 1.05 Million CAD | -11.28% |
| 2016 Q1 | 1.18 Million CAD | 492.2% |
| 2015 Q4 | 199.85 Thousand CAD | 22.58% |
| 2015 FY | 199.85 Thousand CAD | -16.76% |
| 2015 Q1 | 144.3 Thousand CAD | -39.89% |
| 2015 Q3 | 163.04 Thousand CAD | -33.72% |
| 2015 Q2 | 245.98 Thousand CAD | 70.46% |
| 2014 Q2 | 182.17 Thousand CAD | -3.13% |
| 2014 FY | 240.08 Thousand CAD | 6.64% |
| 2014 Q3 | 223.78 Thousand CAD | 22.84% |
| 2014 Q4 | 240.08 Thousand CAD | 7.28% |
| 2014 Q1 | 188.05 Thousand CAD | -16.47% |
| 2013 Q1 | 143.83 Thousand CAD | 7.38% |
| 2013 FY | 225.14 Thousand CAD | 68.08% |
| 2013 Q4 | 225.14 Thousand CAD | 76.39% |
| 2013 Q3 | 127.64 Thousand CAD | -30.74% |
| 2013 Q2 | 184.3 Thousand CAD | 28.13% |
| 2012 Q3 | 128.59 Thousand CAD | -21.14% |
| 2012 Q1 | 139.75 Thousand CAD | 17.38% |
| 2012 FY | 133.95 Thousand CAD | 12.5% |
| 2012 Q2 | 163.06 Thousand CAD | 16.68% |
| 2012 Q4 | 133.95 Thousand CAD | 4.17% |
| 2011 Q3 | 91.34 Thousand CAD | -10.03% |
| 2011 FY | 119.06 Thousand CAD | -17.31% |
| 2011 Q1 | 136.75 Thousand CAD | -5.03% |
| 2011 Q2 | 101.53 Thousand CAD | -25.76% |
| 2011 Q4 | 119.06 Thousand CAD | 30.34% |
| 2010 Q1 | 50.25 Thousand CAD | -50.84% |
| 2010 FY | 143.99 Thousand CAD | 40.87% |
| 2010 Q4 | 143.99 Thousand CAD | 28.88% |
| 2010 Q3 | 111.72 Thousand CAD | 74.48% |
| 2010 Q2 | 64.03 Thousand CAD | 27.42% |
| 2009 FY | 102.22 Thousand CAD | -15.41% |
| 2009 Q2 | 41.28 Thousand CAD | -37.68% |
| 2009 Q3 | 33.78 Thousand CAD | -18.18% |
| 2009 Q4 | 102.22 Thousand CAD | 202.58% |
| 2009 Q1 | 66.25 Thousand CAD | -45.17% |
| 2008 Q1 | 10.32 Thousand CAD | -69.9% |
| 2008 Q3 | 132.93 Thousand CAD | -17.31% |
| 2008 Q2 | 160.77 Thousand CAD | 1457.74% |
| 2008 FY | 120.84 Thousand CAD | 252.45% |
| 2008 Q4 | 120.84 Thousand CAD | -9.1% |
| 2007 Q4 | 34.28 Thousand CAD | -10.32% |
| 2007 Q3 | 38.23 Thousand CAD | -79.75% |
| 2007 Q2 | 188.78 Thousand CAD | 221.03% |
| 2007 Q1 | 58.8 Thousand CAD | -51.86% |
| 2007 FY | 34.28 Thousand CAD | -71.93% |
| 2006 FY | 122.15 Thousand CAD | -49.57% |
| 2006 Q4 | 122.15 Thousand CAD | 78.31% |
| 2006 Q3 | 68.5 Thousand CAD | 6.61% |
| 2006 Q2 | 64.26 Thousand CAD | -78.09% |
| 2006 Q1 | 293.29 Thousand CAD | 21.08% |
| 2005 Q2 | 142.93 Thousand CAD | -6.79% |
| 2005 Q4 | 242.23 Thousand CAD | 26.53% |
| 2005 FY | 242.23 Thousand CAD | 38.6% |
| 2005 Q3 | 191.45 Thousand CAD | 33.94% |
| 2005 Q1 | 153.34 Thousand CAD | -12.26% |
| 2004 Q4 | 174.78 Thousand CAD | -38.35% |
| 2004 Q1 | 313.69 Thousand CAD | 71.99% |
| 2004 FY | 174.78 Thousand CAD | -4.17% |
| 2004 Q2 | 524.51 Thousand CAD | 67.21% |
| 2004 Q3 | 283.49 Thousand CAD | -45.95% |
| 2003 Q3 | 204.03 Thousand CAD | 26.52% |
| 2003 Q4 | 182.39 Thousand CAD | -10.61% |
| 2003 Q2 | 161.26 Thousand CAD | -2.05% |
| 2003 Q1 | 164.64 Thousand CAD | -12.27% |
| 2003 FY | 182.39 Thousand CAD | -2.82% |
| 2002 Q1 | 213.36 Thousand CAD | 0.0% |
| 2002 FY | 187.67 Thousand CAD | -58.07% |
| 2002 Q2 | 133.73 Thousand CAD | -37.32% |
| 2002 Q3 | 154.95 Thousand CAD | 15.86% |
| 2002 Q4 | 187.67 Thousand CAD | 21.12% |
| 2001 FY | 447.62 Thousand CAD | 233.85% |
| 2000 FY | 134.08 Thousand CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | 22.737% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 62.452% |
| Helix BioPharma Corp. | 1.57 Million CAD | -507.491% |
| Microbix Biosystems Inc. | 11.02 Million CAD | 13.023% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | 31.204% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -164.688% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | 14.788% |